DTB podcast
Summary: From June 2023, all our podcasts will move to https://dtbbmj.podbean.com. You can continue with your subscription on your favourite podcast App. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
In April's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the challenges of prescribing direct acting oral anticoagulant (DOAC) drugs for people with renal impairment. The editors also talk about the use of saline nasal irrigation and discuss central sensitisation syndrome. Read the issue online: https://dtb.bmj.com/content/57/4.
In March's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) get excited about the impact that the results of the Direct study could have on the management of type 2 diabetes. The editors also discuss the combination of doxylamine and pyridoxine for the treatment of nausea and vomiting in pregnancy and consider the role of primary care in supporting patients who are taking clozapine. Read the full issue: https://dtb.bmj.com/content/57/3.
In March's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) get excited about the impact that the results of the Direct study could have on the management of type 2 diabetes. The editors also discuss the combination of doxylamine and pyridoxine for the treatment of nausea and vomiting in pregnancy and consider the role of primary care in supporting patients who are taking clozapine. Read the full issue: https://dtb.bmj.com/content/57/3.
In February's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of inhaled corticosteroids in the management of COPD (https://dtb.bmj.com/content/57/2/18). The editors also consider subclinical hypothyroidism in pregnancy (https://dtb.bmj.com/content/57/2/22) and discuss Gilbert’s syndrome (https://dtb.bmj.com/content/57/2/27). Read the full issue: https://dtb.bmj.com/content/57/2
In February's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of inhaled corticosteroids in the management of COPD (https://dtb.bmj.com/content/57/2/18). The editors also consider subclinical hypothyroidism in pregnancy (https://dtb.bmj.com/content/57/2/22) and discuss Gilbert’s syndrome (https://dtb.bmj.com/content/57/2/27). Read the full issue: https://dtb.bmj.com/content/57/2
In January's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether intravenous antibiotics are always needed. The editors also consider the challenge of stopping antipsychotic drug treatment in people with intellectual disability and review a case of angioedema of the small bowel caused by lisinopril. Read the issue: dtb.bmj.com/content/57/1.
In January's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether intravenous antibiotics are always needed. The editors also consider the challenge of stopping antipsychotic drug treatment in people with intellectual disability and review a case of angioedema of the small bowel caused by lisinopril. Read the issue: dtb.bmj.com/content/57/1.
In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the conditional authorisation process for medicines and the need for clearer labelling of medicines that have been through this approval processes. The editors also consider common sources of information on medicines for patients and review a case of interstitial lung disease associated with adalimumab. Read the issue: https://dtb.bmj.com/content/56/12.
In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the conditional authorisation process for medicines and the need for clearer labelling of medicines that have been through this approval processes. The editors also consider common sources of information on medicines for patients and review a case of interstitial lung disease associated with adalimumab. Read the issue: https://dtb.bmj.com/content/56/12.
In November's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a recent study that compared a coordinated, multi-professional, multi-faceted primary care approach to managing people with multiple long-term conditions with usual general practice care. The editors also consider problems faced by patients who need to travel overseas with controlled drugs and review a case of splenic rupture associated with rivaroxaban. Read the November issue: https://dtb.bmj.com/content/56/11.
In November's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a recent study that compared a coordinated, multi-professional, multi-faceted primary care approach to managing people with multiple long-term conditions with usual general practice care. The editors also consider problems faced by patients who need to travel overseas with controlled drugs and review a case of splenic rupture associated with rivaroxaban. Read the November issue: https://dtb.bmj.com/content/56/11.
In October's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the place of population screening for atrial fibrillation and the need for more evidence to support a change in national policy (https://dtb.bmj.com/content/56/10/112). The editors also consider problems associated with long-term opioid use in the management of chronic pain (https://dtb.bmj.com/content/56/10/118). Please watch the video about Michael's moving story on this subject at dtb.bmj.com. The launch of slidenafil as an over-the-counter pharmacy medicine (https://dtb.bmj.com/content/56/10/123) is also discussed. Read the latest from the reinvented Drug and Therapeutics Bulletin here: dtb.bmj.com.
In October's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the place of population screening for atrial fibrillation and the need for more evidence to support a change in national policy (https://dtb.bmj.com/content/56/10/112). The editors also consider problems associated with long-term opioid use in the management of chronic pain (https://dtb.bmj.com/content/56/10/118). Please watch the video about Michael's moving story on this subject at dtb.bmj.com. The launch of slidenafil as an over-the-counter pharmacy medicine (https://dtb.bmj.com/content/56/10/123) is also discussed. Read the latest from the reinvented Drug and Therapeutics Bulletin here: dtb.bmj.com.
In September's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the changes to DTB that have taken place this month and discuss the background and rationale to these changes. Read this month's editorial: https://dtb.bmj.com/content/56/9/98. The editors also consider the place for monitored dosage systems (https://dtb.bmj.com/content/56/9/102) and discuss the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy (https://dtb.bmj.com/content/56/9/107). Meet the new DTB here: https://dtb.bmj.com/content/56/9.
In September's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the changes to DTB that have taken place this month and discuss the background and rationale to these changes. Read this month's editorial: https://dtb.bmj.com/content/56/9/98. The editors also consider the place for monitored dosage systems (https://dtb.bmj.com/content/56/9/102) and discuss the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy (https://dtb.bmj.com/content/56/9/107). Meet the new DTB here: https://dtb.bmj.com/content/56/9.
